Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan
Crossref DOI link: https://doi.org/10.1007/s12094-017-1706-2
Published Online: 2017-07-03
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Uhara, H. http://orcid.org/0000-0001-5391-3397
Kiyohara, Y.
Tsuda, A.
Takata, M.
Yamazaki, N.
Funding for this research was provided by:
Chugai Pharmaceutical
License valid from 2017-07-03